E-Cig Use
Conditions
Keywords
Microvascular Health
Brief summary
The study is focused on investigating the mechanisms involved in microvascular health in subjects that use e-cigarettes frequently. To explore microvascular health, different techniques and compounds. For one of the tests, iontophoresis, the drug's use will be stored and handled as described by the approved IND and non-IDS plan.
Detailed description
Electronic cigarettes or e-cigarettes have become increasingly popular, due to their promotion as a healthy alternative to traditional tobacco cigarettes. However, there are large discrepancies of knowledge in understanding how these e-cigarettes affect the subjects health and the way their body uses oxygen. The overall goal of this study is to evaluate e-cigarettes usage on subjects health.
Interventions
OTHERE-cig use
Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes
Sponsors
Virginia Commonwealth University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 29 Years
Healthy volunteers
Yes
Inclusion criteria
e-Cig users arm Inclusion Criteria: * Between 18 and 29 years of age * Used e-cigarettes with nicotine (≥3 times/week for ≥6 months)
Exclusion criteria
* 17 years old and younger or 30 years old or older. * Former combustible tobacco user/ former smoker * Use of cigarettes for 15 days or more in the past 60 days * Use of other tobacco products (cigars, hookah, smokeless), marijuana and/or illicit or prescription drugs weekly or more frequently in the past 60 days * Evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders * Disorder or use of medication that affects cardiopulmonary health * Evidence of pregnancy or current nursing Non e-Cig using arm Inclusion \- Between 18 and 29 years of age Exclusion * 17 years old and younger or 30 years old and older * Use of cigarettes or other tobacco products more than 50 times in their lifetime. * Evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders * Disorder or use of medication that affects cardiopulmonary health * Evidence of pregnancy or current nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endothelial dependent dilation | Participation is one week | Endothelial-dependent dilation will be assessed using laser doppler speckle contrast in both groups through the intervention |
| Neurogenic response | Participation is one week | Neurogenic response will be assessed using axon reflex in both groups through the intervention |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORPaula Rodriguez Miguelez
Virginia Commonwealth University
Outcome results
None listed